Taken together, these results demonstrated that hepatocellular ablation of Hsp90β prevented HFFC-induced hepatic steatosis, inflammation, and fibrosis, suggesting that Hsp90β was required for Shh-triggered NASH development. The gene discussed is SHH; the disease is metabolic dysfunction-associated steatohepatitis.